Peptides for Erectile Dysfunction and Male Sexual Health: What the Evidence Actually Shows

Search "peptides for ED" and the same names come up: PT-141 (bremelanotide), melanotan II, occasionally oxytocin, and a rotating cast of growth-hormone secretagogues claimed to improve libido. The wellness community treats these as a category of "natural alternatives" to Viagra or testosterone replacement.

They aren't quite that. The clinical evidence for peptides in male sexual function is real but limited, and the FDA approval picture is narrower than the marketing suggests. PT-141 is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, not for men. Melanotan II shares the same receptor family but has a worse safety profile and is unlicensed in every major regulatory jurisdiction. GLP-1 drugs may improve erectile function indirectly through weight loss and hormonal recovery, but the data is observational and emerging rather than randomized.

This article maps the actual clinical evidence for each major peptide class men ask about for sexual function. The short version: PT-141 is the most legitimate peptide in the space, with real Phase 3 evidence in women and small off-label studies in men; melanotan II shares the mechanism but carries real safety concerns; GLP-1s offer indirect benefits worth understanding; and the rest is marketing running ahead of the trials.

About 40% of men over 40 experience some degree of erectile dysfunction. The diagnostic categories matter because they predict what works.

Vascular ED is the most common cause, driven by reduced blood flow from atherosclerosis, hypertension, or diabetes. Neurogenic ED follows nerve damage from prostate surgery, spinal cord injury, or peripheral neuropathy. Hormonal ED tracks low testosterone and other endocrine deficiencies. Psychogenic ED is performance anxiety, depression, or relationship-driven, often layered on top of other causes. And there's drug-induced ED. SSRIs, beta blockers, finasteride, and dozens of other prescriptions affect sexual function in ways that often resolve when the drug is changed.

Most men have a mix. A 50-year-old with mild hypertension, borderline testosterone, an SSRI for anxiety, and a busy life isn't going to be fixed by one intervention. The peptide approach often gets framed as a single solution to a complex problem, which is part of why expectations run ahead of results.

Standard first-line treatment is PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis, vardenafil/Levitra). They work for about 70% of men with vascular ED and have decades of safety data. For hormonal causes, testosterone replacement therapy when clinically indicated. For neurogenic ED after prostate surgery, intracavernosal injection or vacuum erection devices. Peptides enter the picture when these standard options don't fit (contraindications, side effects, partial response) or when men want to address something more specific than mechanical erection, such as desire, satisfaction, or hormonal recovery.

PT-141, brand name Vyleesi, is the closest thing to an FDA-approved sexual-function peptide. The FDA approved it in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed by Palatin Technologies and later Cosette Pharmaceuticals.

The mechanism makes it unique. PT-141 activates melanocortin receptors (primarily MC4R and MC3R) in the central nervous system, which sit upstream of the desire and arousal pathways in the hypothalamus. Unlike PDE5 inhibitors, which improve blood flow to the penis, PT-141 acts on the brain's sexual-response circuitry directly. The drug doesn't require sexual stimulation to work, doesn't depend on vascular function, and can produce both desire and arousal in users.

The female Phase 3 program (RECONNECT trials) led to the Vyleesi approval. The male data is much smaller. Early Phase 2 work in men with ED showed improvements in erectile function, but the male program was deprioritized because of cardiovascular side effects (transient blood-pressure increases) and because PDE5 inhibitors covered most of the same therapeutic territory with better data. The most-cited published studies in men include a 2002 trial showing erectile improvement on intranasal PT-141 versus placebo, and several small later studies in PDE5-inhibitor non-responders.

Off-label use in men is widespread. The drug is administered subcutaneously (or intranasally in compounded form), typically at doses of 0.5-1.75 mg per dose, taken 45 minutes to an hour before activity. Common side effects include nausea (the most-reported, sometimes severe), flushing, headache, and transient blood-pressure increase. Men with uncontrolled hypertension or cardiovascular disease should not use it without cardiologist input.

The honest read: PT-141 has the strongest real-trial evidence of any peptide in the male-sexual-function space, but most of that evidence is in women. Off-label male use is reasonable for PDE5-non-responders or men who want a central-acting rather than vascular intervention, with realistic expectations about side effects.

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone that activates the same melanocortin receptor family as PT-141, plus MC1R (the receptor responsible for skin pigmentation). It was originally developed at the University of Arizona in the 1980s as a tanning agent and abandoned commercially. The intellectual lineage that produced PT-141 came from that early melanotan work.

Melanotan II has been used off-label for both tanning and ED, often by men hoping for two effects from one compound. The mechanism for the ED claim is the same MC4R/MC3R central activation that PT-141 uses. Anecdotal reports of erectile improvement are common; controlled trials in men with ED are missing from the literature.

The safety profile is where melanotan II diverges from PT-141 sharply. The compound is unlicensed in every major regulatory jurisdiction. Case reports have linked melanotan II use to changing or new pigmented skin lesions, including melanoma. The 2025 wave of TikTok-driven nasal-spray melanotan II products produced multiple regulatory warnings and at least one reported pediatric exposure. UK and Australian regulators have issued formal alerts. The melanotan II safety profile is one of the cleaner examples of why peptide drugs with real receptor activity should not be casually self-administered without medical supervision.

For a deeper dive on the melanotan I versus II distinction (afamelanotide, the FDA-approved cousin, versus the underground TikTok product), see our tanning peptides deep dive. The short version for ED specifically: PT-141 has more clinical evidence and a much better safety profile. There is no rational reason to choose melanotan II over PT-141 for sexual function purposes.

GLP-1 receptor agonists like semaglutide and tirzepatide aren't sexual-function drugs, but they affect erectile function through several indirect pathways that have started to show up in clinical data.

The most direct mechanism is vascular. Erectile dysfunction is one of the earliest manifestations of small-vessel atherosclerosis. Drugs that improve cardiovascular risk profile (lower BMI, better lipids, lower blood pressure, reduced inflammation) tend to improve erectile function over time. The SELECT cardiovascular outcomes trial showed semaglutide reduces major adverse cardiovascular events; that benefit extends to the small vessels in the penis.

The second mechanism is hormonal. About 40-50% of men with obesity have low testosterone, driven by the obesity-testosterone cycle (body fat converts testosterone to estrogen via aromatase, the estrogen feedback-suppresses brain GnRH signaling, testosterone production drops further). GLP-1-driven weight loss can run that cycle in reverse: a UK meta-analysis presented at ENDO 2026 found 24 weeks of GLP-1 treatment improved testosterone levels, sperm count, and sperm morphology in men with obesity-related low testosterone. We covered this in detail in our GLP-1s and male fertility piece. The fertility data and the ED data overlap heavily because testosterone is downstream of both.

The third mechanism is psychological: weight loss, energy restoration, and improved confidence have non-trivial effects on libido and performance.

For men with obesity-related ED, the realistic order of operations is GLP-1 weight loss first (which addresses the underlying vascular, hormonal, and psychological drivers), with PDE5 inhibitors as the on-demand fix while body composition catches up. PT-141 enters as an option for men who don't respond to PDE5s or who specifically want central-acting desire and arousal effects.

TRT is the standard medical treatment for clinically low testosterone (typically below 300 ng/dL with symptoms). It's not a peptide drug (testosterone is a steroid hormone), but it's frequently confused with peptide protocols and discussed alongside them.

For men with documented hypogonadism causing ED, TRT often improves erectile function within 3-6 months. Combined with PDE5 inhibitors, response rates approach 80% in men whose ED is primarily hormonal. TRT formulations include injections (testosterone cypionate, enanthate), gels (AndroGel, Testim), and pellets (Testopel).

The major TRT catch for men in their reproductive years: external testosterone suppresses the brain's signal to the testes (via LH and FSH suppression), which can drop sperm production substantially. Men on TRT who want to father children typically pair it with HCG, clomiphene, or other agents that preserve testicular function. This trade-off is the central reason the GLP-1 fertility data matters: GLP-1-driven weight loss may restore natural testosterone production through the obesity-testosterone cycle without the fertility suppression TRT causes.

If you have classic low-T symptoms (fatigue, low libido, ED, mood changes, reduced muscle mass) and your serum testosterone is below 300 ng/dL on morning labs, TRT is the right starting point, not a wellness peptide. Get a full hormonal panel including LH, FSH, estradiol, SHBG, and prolactin to identify whether the cause is primary (testicular) or secondary (pituitary or hypothalamic). The cause guides the treatment.

Sermorelin, CJC-1295, and ipamorelin are growth-hormone secretagogues that raise endogenous GH and IGF-1. Users frequently report libido improvements as a secondary effect. The mechanism is poorly characterized: GH and IGF-1 have downstream effects on multiple endocrine axes, and some men with mild GH deficiency report broader recovery of energy and sexual function on these protocols.

The controlled trial evidence in male sexual function specifically is sparse to absent. No Phase 3 trial, no published RCTs in ED, no head-to-head data against PDE5 inhibitors or TRT. The anecdotal pattern is consistent enough that the effect is probably real for a subset of users, likely those with subclinical hormonal deficiency rather than confirmed hypogonadism, though the data does not support recommending GH secretagogues as a primary ED intervention.

For men interested in the GH secretagogue class for general anti-aging or recovery purposes, libido improvement may be a welcome side effect. For men whose primary concern is ED, the order of operations remains PDE5s first, TRT if hormonal, GLP-1 if weight-related, PT-141 if central-acting is wanted. GH secretagogues come later in the decision tree, if at all.

Intranasal oxytocin is another peptide that comes up in male-sexual-health discussions, marketed for emotional connection, bonding, and orgasm intensity. The published research is thinner than the marketing suggests.

Oxytocin is the endogenous peptide hormone responsible for childbirth contractions, lactation, and social bonding. Small studies have explored intranasal oxytocin for relationship satisfaction, trust, and a handful of psychiatric indications. The sexual-function data is limited to small uncontrolled studies and anecdotal reports. There is no RCT showing intranasal oxytocin improves erectile function or libido in a way that meets evidence standards.

The blood-brain-barrier crossing of intranasal oxytocin is also a subject of ongoing scientific debate. Even if the drug reaches plasma, whether it crosses into CNS tissue at functionally relevant concentrations is not fully established.

The practical takeaway: oxytocin is a peptide-curious option with a plausible mechanism for bonding effects and very thin evidence for sexual function. It belongs in the experimental category, not the recommended-treatment category.

Here's how to think about peptides for male sexual function if you're considering them seriously.

First, work up the cause. A 50-year-old with new-onset ED needs a cardiovascular evaluation: ED is often the earliest sign of small-vessel atherosclerosis, and treating the symptom without the underlying disease misses the bigger problem. Get a full lipid panel, blood pressure assessment, and consider a cardiologist consult before adding any peptide.

Second, check hormones. Morning testosterone, LH, FSH, estradiol, SHBG, prolactin, and TSH catch most of the endocrine causes. Low-T with symptoms below 300 ng/dL is a TRT question, not a peptide question (unless GLP-1 weight loss is in play for obesity-related hypogonadism, in which case it can come first).

Third, try PDE5s. Sildenafil and tadalafil are first-line for a reason. They work for the majority of men with vascular ED, are safe under most conditions, and are cheap in generic form. Talk to a primary care doctor or urologist about dosing and contraindications.

Fourth, if PDE5s don't work or aren't suitable, PT-141 is the most evidence-supported peptide alternative. Use a licensed compounding pharmacy with a real prescription. Start at the low end of dosing (0.5 mg subcutaneous) to assess tolerance and blood-pressure response. Avoid melanotan II (same receptors, worse safety profile).

Fifth, if you have obesity and ED, GLP-1 weight loss addresses multiple causes at once and is the highest-evidence peptide-class intervention for the underlying problem. Talk to your prescriber about semaglutide, tirzepatide, or retatrutide once approved.

Sixth, the basics still matter. Sleep, exercise, alcohol moderation, smoking cessation, stress management. These move the needle on erectile function more than most pharmacologic interventions, and they support whatever drug protocol you're on.

PT-141 (bremelanotide) is the most legitimate peptide in the male-sexual-function space, with real FDA approval in women, off-label evidence in men, and a defined mechanism distinct from PDE5 inhibitors. Melanotan II shares the receptors with worse safety. GLP-1 drugs improve erectile function indirectly through weight loss, vascular health, and testosterone restoration. For obese men with ED, they may address the underlying cause better than any symptom-targeted intervention. Testosterone replacement is the right answer for hormonal ED but suppresses fertility. Sermorelin, CJC-1295, and oxytocin sit in the experimental tier with anecdotal libido reports and minimal trial data.

The order of operations matters. Diagnose the cause. Check hormones. Try PDE5s. Then layer peptides for what they're actually good at, not as a single replacement for the standard pathway. The wellness community's framing of peptides as a unified ED solution runs ahead of the evidence; the actual evidence-supported approach is more methodical and more boring, and it works better.